Physician profile
Michael A Sterner
NPI 1083296073
$2,366.18
in general payments reported to CMS, 2019-2025
22 companies · $585 in 2025
The $585 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $136 · 2022: $366 · 2023: $801 · 2024: $478 · 2025: $585.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,864.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,864.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $375.74 | 2023 | |
| Emd Serono, INC. | $250.00 | 2023-2024 | |
| Nevro Corp. | $143.20 | 2024 | Senza |
| E.R. Squibb & Sons, L.L.C. | $124.74 | 2023 | Eliquis |
| Grifols USA, LLC | $124.16 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $122.91 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $121.35 | 2023 | Cuvitru |
| Bayer Healthcare Pharmaceuticals INC. | $119.70 | 2025 | |
| Abbvie INC. | $116.49 | 2024-2025 | |
| Novo Nordisk INC | $113.77 | 2022 | |
| Horizon Therapeutics Plc | $113.40 | 2022 | |
| Neurelis, INC. | $113.34 | 2025 | Valtoco |
| Amgen INC. | $108.89 | 2023-2025 | Krystexxa, Blincyto, Kyprolis |
| Axsome Therapeutics, INC. | $105.71 | 2025 | Auvelity |
| Gilead Sciences, INC. | $100.59 | 2025 | Epclusa |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $47.59 | 2024 | Mounjaro |
| Organon LLC | $33.16 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $30.61 | 2022-2023 | Vaxelis, Vaxneuvance, Gardasil 9 |
| Dynavax Technologies Corporation | $30.43 | 2025 | Heplisav-B |
| Sumitomo Pharma America, INC. | $27.18 | 2024 | Myfembree |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.34 | 2024 | Trulance |
| Exact Sciences Corporation | $19.88 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Sterner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.